2-HOBA to reduce persistent immune activation in Long COVID with POTS

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial compares 28 days of oral 2‑HOBA versus placebo in people with Long COVID and postural orthostatic tachycardia syndrome (POTS). Investigators will measure circulating monocyte–T cell complexes (doublets) and splanchnic venous capacitance at baseline and after treatment to track immune activation and hemodynamic changes. The study builds on findings that reduced parasympathetic activity and NADPH oxidase–driven oxidative stress increase IsoLG‑adduct formation in LCPOTS. Results will determine whether scavenging IsoLGs with 2‑HOBA lowers markers linked to persistent immune responses and orthostatic dysfunction.

Why it matters

Who can join: the full rules

Inclusion Criteria:

All participants should meet diagnostic criteria for Long COVID and POTS and as outlined below:

Long COVID (LC) is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection.

POTS: the presence of chronic symptoms lasting more than 3 months, along with orthostatic tachycardia (a HR increase over 30 bpm upon standing or exceeding 120 bpm without orthostatic hypotension) within 10 minutes upon standing or 75-degree head up tilt.

For patients aged 18 and 21, an increase of more than 40 bpm or a standing HR over 130 bpm will be required for inclusion in the study.

2 Patients need confirmation of POTS diagnosis based on orthostatic vital signs obtained prior to enrollment in the study.

SARS-CoV-2 infection 3 or more months prior identified by the follow signs:

A. Meets the clinical OR epidemiological criteria.

1. Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia.
2. Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID-19 cluster; or B. Presents with acute respiratory infection with history of fever or measured fever of ≥ 38°C; and cough; with onset within the last 10 days; and who requires hospitalization); or C. Presents with no clinical signs or symptoms, NOR meeting epidemiologic criteria with a positive professional use or self-test SARS-CoV-2 antigen-Rapid Diagnostic Test.

D. A person with a positive nucleic acid amplification test, regardless of clinical criteria OR epidemiological criteria; or E. Meeting clinical criteria AND/OR epidemiological criteria (See A). With a positive professional use or self-test, SARS-CoV-2 Antigen-Rapid Diagnostic Test.

F. Documented by health care provider in clinical note or encounter.

Exclusion Criteria:

1. Known active acute SARS-Cov-2 infection (4 weeks from onset)
2. Moderate or severe immunocompromised patients,
3. Known history of cardiovascular disease (atrioventricular block (AV block), myocardial infarction, angina, heart failure, pacemaker, stroke, transient ischemic attack within 6 months before enrollment),
4. Uncontrolled hypertension (BP\>140/90 despite appropriate treatment);
5. Type 1 or type 2 diabetes mellitus;
6. Impaired hepatic function (AST or ALT greater than 1.5x the upper limit of normal or with total bilirubin ≥1.5mg/dl),
7. Impaired renal function test (eGFR\<60 mL/min/1.73m2),
8. Anemia (hemoglobin \<10 g/dl),
9. Pregnant or breastfeeding women,
10. Known history of autoimmune disease, steroid use or other immunotherapies,
11. Inability to provide informed consent.

We will also exclude individuals with known allergy sensitivity to components of the study medication, known contraindication to the study interventions, use of central acetylcholinesterase inhibitors (e.g., pyridostigmine, donezepil), aspirin allergy because salicylic acid is a metabolite of 2-HOBA; use of monoamine oxidase inhibitors (MAO-I) because of some inhibition of MAO-A is present in the anticipated therapeutic range of 2-HOBA.

\-

Where it's running

• Cyndya Shibao
  Nashville, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Cyndya Shibao, M.D — Vanderbilt University Medical Center
• Study coordinator: Marwa Mohamed, PhD
• Email: marwa.mohamed@vumc.org
• Phone: 6159702384

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long COVID relief through learning mindfulness

  This study will try an 8-week online recorded mindfulness program to see if it reduces stress and Long COVID symptoms in adults who continue their usual care.

  Recruiting Columbia University · New York, New York · NCT07140094

• Transcranial Direct Current Stimulation for Long COVID with Headaches and Chronic Pain

  This study tests whether applying mild brain stimulation (tDCS) can help people with long COVID who have headaches, migraines, and ongoing pain.

  Recruiting at 2 sites Fundación Universidad Católica de Valencia San Vicente Mártir · Paiporta, Valencia and 1 other locations · NCT05780450

• Cardiovascular health five years after MIS-C in children

  This study tests whether kids who had MIS-C still show cardiovascular differences five years later compared with healthy peers.

  Recruiting Medical University of Warsaw · Warsaw, Masovian Voivodeship · NCT07659847

• Second cohort following patients entering a multidisciplinary care pathway for post-COVID syndromes (SyPoCo2)

  This project will test whether linking long COVID patients' symptoms with blood immune and molecular markers can find biomarkers and possible treatment targets.

  Recruiting at 2 sites Hospices Civils de Lyon · Pierre-Bénite and 1 other locations · NCT07356570

• Remdesivir to prevent severe COVID-19 in kidney transplant patients

  This study will try giving remdesivir around the time of transplant to see if it prevents severe COVID-19 in adults receiving a kidney transplant who are currently SARS‑CoV‑2 positive with no or mild symptoms.

  Recruiting Phase 2 Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Badalona, Barcelona · NCT07197164

• Accelerated intermittent theta-burst stimulation for depression with post‑COVID‑19 condition

  This will test whether two different schedules of intermittent theta-burst stimulation (accelerated TMS) reduce depressive symptoms and inflammation in adults aged 18–65 who have depressive disorder plus post‑COVID‑19 condition.

  Recruiting Max-Planck-Institute of Psychiatry · Munich, Bavaria · NCT07197138

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.